| Primary |
| Premedication |
38.5% |
| Prophylaxis |
13.6% |
| Prophylaxis Of Nausea And Vomiting |
8.9% |
| Breast Cancer Recurrent |
7.7% |
| Metastases To Bone |
7.7% |
| Breast Cancer |
4.1% |
| Drug Use For Unknown Indication |
3.6% |
| Pancreatic Neoplasm |
3.6% |
| Breast Cancer Metastatic |
3.0% |
| Rectal Cancer Metastatic |
1.8% |
| Antiemetic Supportive Care |
1.2% |
| Glioblastoma |
1.2% |
| Nausea |
1.2% |
| Vomiting |
1.2% |
| Analgesic Therapy |
0.6% |
| Anticachectic Therapy |
0.6% |
| Gastric Cancer |
0.6% |
| Mantle Cell Lymphoma |
0.6% |
| Pain |
0.6% |
|
| Pulmonary Artery Thrombosis |
17.2% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
10.3% |
| Death |
6.9% |
| Myalgia |
6.9% |
| Tumour Lysis Syndrome |
6.9% |
| Alopecia |
3.4% |
| Decreased Appetite |
3.4% |
| Dyskinesia |
3.4% |
| Fatigue |
3.4% |
| Febrile Neutropenia |
3.4% |
| Gastrointestinal Perforation |
3.4% |
| Haemolytic Anaemia |
3.4% |
| Hepatitis Cholestatic |
3.4% |
| Hyperventilation |
3.4% |
| Ileus |
3.4% |
| Injection Site Extravasation |
3.4% |
| Lung Neoplasm Malignant |
3.4% |
| Lymphopenia |
3.4% |
| Malaise |
3.4% |
| Neutropenia |
3.4% |
|
| Secondary |
| Premedication |
26.7% |
| Breast Cancer |
12.1% |
| Prophylaxis Of Nausea And Vomiting |
11.1% |
| Prophylaxis |
7.9% |
| Breast Cancer Metastatic |
7.0% |
| Breast Cancer Recurrent |
6.5% |
| Rectal Cancer Metastatic |
5.8% |
| Metastases To Bone |
5.3% |
| Acute Lymphocytic Leukaemia |
3.2% |
| Therapeutic Embolisation |
2.8% |
| Drug Use For Unknown Indication |
2.1% |
| Product Used For Unknown Indication |
1.9% |
| Evidence Based Treatment |
1.4% |
| Gastric Cancer |
1.4% |
| Rectal Cancer |
1.2% |
| B-cell Lymphoma |
0.9% |
| Antifungal Prophylaxis |
0.7% |
| Colon Cancer Metastatic |
0.7% |
| Dyspnoea |
0.7% |
| Feeling Hot |
0.7% |
|
| Inappropriate Antidiuretic Hormone Secretion |
12.2% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
10.2% |
| Pulmonary Artery Thrombosis |
10.2% |
| Renal Impairment |
8.2% |
| Alopecia |
6.1% |
| Injection Site Extravasation |
6.1% |
| Stomatitis |
6.1% |
| Swollen Tongue |
6.1% |
| Anaphylactic Shock |
4.1% |
| Fatigue |
4.1% |
| Malaise |
4.1% |
| Metastases To Bone |
4.1% |
| Rash |
4.1% |
| Constipation |
2.0% |
| Death |
2.0% |
| Decreased Appetite |
2.0% |
| Dehydration |
2.0% |
| General Physical Health Deterioration |
2.0% |
| Hepatitis Cholestatic |
2.0% |
| Hyponatraemia |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
38.7% |
| Prophylaxis |
13.3% |
| Infection Prophylaxis |
6.6% |
| Premedication |
5.5% |
| Bone Marrow Conditioning Regimen |
5.3% |
| Prophylaxis Against Graft Versus Host Disease |
5.0% |
| Drug Use For Unknown Indication |
3.9% |
| Prophylaxis Of Nausea And Vomiting |
3.9% |
| Antifungal Prophylaxis |
2.4% |
| Constipation |
2.0% |
| Colon Cancer |
1.7% |
| Breast Cancer |
1.7% |
| Antiviral Prophylaxis |
1.5% |
| B-cell Lymphoma |
1.5% |
| Acute Myeloid Leukaemia |
1.3% |
| Extranodal Marginal Zone B-cell Lymphoma (Malt Type) |
1.3% |
| Antibiotic Prophylaxis |
1.1% |
| Colorectal Cancer |
1.1% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.1% |
| Hypertension |
1.0% |
|
| White Blood Cell Count Decreased |
19.3% |
| Tumour Lysis Syndrome |
13.8% |
| Pyrexia |
9.3% |
| Vomiting |
7.8% |
| Neutropenia |
5.2% |
| Platelet Count Decreased |
4.8% |
| Cytomegalovirus Infection |
3.3% |
| Hiccups |
3.3% |
| Wound Complication |
3.3% |
| Cerebral Infarction |
3.0% |
| Decreased Appetite |
3.0% |
| Febrile Neutropenia |
3.0% |
| Pruritus |
3.0% |
| Stomatitis |
3.0% |
| Tooth Loss |
3.0% |
| Infection |
2.6% |
| Pneumonia |
2.6% |
| Device Related Infection |
2.2% |
| Hepatic Function Abnormal |
2.2% |
| Lymphocyte Count Decreased |
2.2% |
|
